Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Dose-Exploration Cohort Study Evaluating the Efficacy and Safety of Voclosporin in Achieving Complete or Partial Remission of Proteinuria in Subjects With Focal Segmental Glomerulosclerosis

NCT03598036 is registered in ClinicalTrials.gov with Aurinia Pharmaceuticals Inc. as lead sponsor.

NCT NCT03598036
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03598036 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Dose-Exploration Cohort Study Evaluating the Efficacy and Safety of Voclosporin in Achieving Complete or Partial Remission of Proteinuria in Subjects With Focal Segmental Glomerulosclerosis
Lead sponsor
Aurinia Pharmaceuticals Inc.
Phase
Phase 2
Overall status
Terminated
Start date
June 21, 2018
Completion date
May 19, 2020
Enrollment
5 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

focal segmental glomerulosclerosis